secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001819790-24-000109
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q2 2024: XDEMVY net sales $40.8M (65% QoQ), net loss $33.3M, gross-to-net improves to 44%
--------------------------------------------------------------------------------

- XDEMVY net product sales $40.8M in Q2, up 65% over Q1; year-to-date $65.5M.
- Gross-to-net discount improved to 44% from 55% in Q1; steady state expected low 40% in 2025.
- More than 37,000 bottles delivered to patients in Q2; ~11,000 ECPs have started patients launch-to-date.
- Net loss $33.3M (($0.88) per share) vs $31.4M in Q2 2023; SG&A $58.8M vs $20.3M due to launch costs.
- Cash $323.6M including ~$39.6M from new credit facility draw; sales force expansion to ~50 additional reps by end of Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000109/0001819790-24-000109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000109/tars-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001819790-24-000109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer